Document Detail


Pharmacogenomics and adverse drug reactions: the case of statins.
MedLine Citation:
PMID:  21568825     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: The use of genomics to predict adverse drug reactions (ADRs) has been the subject of much research over the last decade. Concerns about the muscular safety of statins, a highly prescribed group of drugs, are partially related to their high exposure. Many studies have identified a variety of genetic markers related to statin-induced myopathy. However, only polymorphisms in the SLCO1B1 gene (which encodes the carrier responsible for the hepatic uptake of statins, which, in turn, contributes to the regulation of plasma levels of SLCO1B1) were strongly associated with statin-induced muscular adverse effects. These was found to be most prominent for simvastatin. The strength of these findings relies on the use of modern genetic approaches, such as well-designed, case-controlled and genome-wide association studies. Nevertheless, the clinical use of this information is far from known at present and needs to be evaluated.
AREAS COVERED: The links between genetic polymorphisms (i.e., SLCO1B1 gene) and statin-induced muscle ADRs and the methodological issues involved in the establishment of such an association are explored.
EXPERT OPINION: Despite there being a statin-gene association for myopathy, in the case of some statins the usefulness of this information still needs to be proven.
Authors:
Mariano A Giorgi; Christian Caroli; Hernán Cohen Arazi; Guillermo Di Girolamo
Related Documents :
18416845 - Ser80ile mutation and a concurrent pro25leu variant of the vhl gene in an extended hung...
11181085 - A novel mutation lacking the bromodomain of the transcriptional coactivator p300 in the...
15756445 - Infrequent mutation of the human envoplakin gene is closely linked to the tylosis oesop...
8962135 - The mutation rate and cancer.
24682045 - Identification of chrna5 rare variants in african-american heavy smokers.
20723045 - Genetic diversity and differentiation at mhc genes in island populations of tuatara (sp...
Publication Detail:
Type:  Journal Article; Review     Date:  2011-03-29
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  12     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-06-09     Completed Date:  2011-09-28     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1499-509     Citation Subset:  IM    
Copyright Information:
© 2011 Informa UK, Ltd.
Affiliation:
Department of Cardiology and Cardiovascular Surgery, Montañeses 2325 (1428), FLENI, Buenos Aires, Argentina. marianogiorgi@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Genetic Markers
Genome-Wide Association Study
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*,  pharmacokinetics
Liver / metabolism
Muscular Diseases / chemically induced*,  genetics
Organic Anion Transporters / blood,  genetics
Pharmacogenetics*
Polymorphism, Genetic
Simvastatin / adverse effects
Chemical
Reg. No./Substance:
0/Genetic Markers; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Organic Anion Transporters; 0/SLCO1B1 protein, human; 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sensory acceptability of iron-fortified millet products.
Next Document:  Mitochondrial quality control and dynamics in Parkinson's disease.